MUC16 and benign neoplasm: In this study we analyzed the Olink® Oncology II and Inflammation panels (in total 177 unique protein biomarkers) in 180 women with benign tumor, borderline tumor, early (stage I) or late (stage II-IV) EOC, with the aim of searching for new candidate biomarkers with the potential to improve the performance of HE4 and CA125 for discrimination between benign disease and EOC.